Roberto Vélez Villa Institutions of which they are part Head of group Musculoskeletal Tissue Engineering Vall Hebron Institut de Recerca Email Roberto Vélez Villa Email Institutions of which they are part Head of group Musculoskeletal Tissue Engineering Vall Hebron Institut de Recerca
Research lines Orthopaedic oncology - 3D planification / printing This research line seeks the development of new treatments and new surgical techniques of limb salvage in orthopaedic oncology. Surgical treatments of patients with bone tumours use free bone grafts, vascularized bone grafts or from donors in order to solve massive bone loss. Long surgeries, radiotherapy or chemotherapy could be factors that negatively affect the bone integration of these bone grafts, increasing complications rates such as non-unions, infections or graft fractures. Research in this field search solutions to decrease graft consolidation time, increase their revitalization and decrease infection rates, and develop new treatment alternatives for limb salvage affected with bone tumours. Development of new 3D printing techniques applied to orthopaedic oncology can allow development of new prostheses with biocompatible materials, surgical guides and customized 3D models depending on each tumour lesion. Current research: 1. Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY). A Multi-Center Randomized Controlled Study Comparing Alternative Antibiotics Regimens in Patients Undergoing Tumor Resections with Endoprosthetic Replacements 2. Preclinical study on the revitalization of bone allografts with vascularized periosteal grafts in a rat animal model. Preclinical study to verify the osteoproductive, revitalizing and osteointegrative capacity of a vascularized periosteal graft associated with a structural bone allograft. 3. 3D Planification / Printing 3D planification precision and personalised osteotomy guides in pelvic tumour surgery. Pilot study. IP: Roberto Vélez Villa Bone Regeneration This research line seeks to promote bone regeneration using advanced cell therapy. Our alliance between biologists, engineers and clinical researchers enables us to develop new tissue engineering products that after thorough evaluation in the scopes of basic research and preclinical testing can then be applied in the human clinical setting. Current Studies: 1. Autologous cell therapy with adult stem cells for osteonecrosis of the femoral head. Osteonecrosis Clinical phase I-II study: We are currently conducting a comparative study between a product developed by our research group of advanced cell therapy in the context of osteonecrosis of the femoral head precollapse stage. It is a pioneering study at a national and international level by assessing the bone regenerative capability of this product compared to the classical treatment of core decompression. 2. Treatment of femoral head osteonecrosis with advanced cell therapy and biomaterials in an experimental sheep model. Osteonecrosis preclinical study: We are evaluating mesenchymal stem cells expanded ex-vivo associated with different scaffolds and BMP in osteonecrosis of the femoral head in an ovine model. We are evaluating the different osteoconductive, osteoinductive and osteogenerative components to optimize the best biologic for the treatment of femoral head necrosis. 3. Experimental study of "in vivo" expanded adult stem cell therapy . Critical size defect preclinical study: We are evaluating mesenchymal stem cells expanded ex-vivo in a critical segmental defect in an ovine model. IP: Màrius Aguirre Canyadell, Roberto Vélez Villa Projects Traslación de un producto alogénico de ingeniería tisular para el tratamiento de lesiones focales del cartílago articular IP: Roberto Vélez Villa Collaborators: Nayana Joshi Jubert, Anna Server Salvà, Daniel Alejandro Pacha Vicente, Joan Albert Prat Matifoll, Raquel Cabrera Perez, Sara Morini Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00877 Duration: 01/01/2022 - 30/06/2025 Traslación de un producto alogénico de ingeniería tisular para el tratamiento de lesiones focales del cartílago articular. IP: Joaquim Vives Armengol Collaborators: Roberto Vélez Villa, Nayana Joshi Jubert, Anna Server Salvà, Juan Minguell Moñart, Irene Portas Torres, Raquel Cabrera Perez Funding agency: Instituto de Salud Carlos III Funding: 105270 Reference: PI22/01906 Duration: 01/01/2023 - 31/12/2025 TRASLACIÓN DE UN PRODUCTO DE INGENIERÍA TISULAR ALOGÉNICO CON MSC DE GELATINA DE WHARTON PARA EL TRATAMIENTO DE LA OSTEONECROSIS EN PACIENTES ONCOLÓGICOS PEDIÁTRICOS. IP: Joaquim Vives Armengol Collaborators: Roberto Vélez Villa, Nayana Joshi Jubert, Lluis Martorell Cedres, Maria Cristina Díaz de Heredia Rubio, Màrius Aguirre Canyadell, Irene Portas Torres, Raquel Cabrera Perez Funding agency: Instituto de Salud Carlos III Funding: 87120 Reference: PI19/01788 Duration: 01/01/2020 - 30/06/2024 Musculoskeletal Tissue Engineering IP: - Collaborators: Roberto Vélez Villa Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2017SGR00719 Duration: 01/01/2017 - 31/12/2020 Pagination Current page 1 Page 2 Page 3 Next page › Last page »
